Hangzhou Polymed Biopharmaceuticals Inc. has synthesized crystalline forms of compounds acting as FLT3 (FLK2/STK1) and interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be ...
Kymera Therapeutics Inc. has patented new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 ...